We also found that CCNE2 expression was upregulated by EPT and attenuated by acolbifene, an estrogen receptor antagonist, in breast cancer cells, and the higher expression of CCNE2 correlated with the progress and poor overall survival in breast cancer patients. This evidence concerns the gene CCNE2 and breast carcinoma.